186550-31-2

Upstream product

• 56875-60-6 7-Methoxy-2-naphthalenesulfonyl chloride 
• 135-55-7 7-hydroxynaphthalene-2-sulfonic acid sodium salt 
• 186550-17-4 [1-(3-cyanobenzyl)-2-oxopyrrolidin-3(S)-yl]carbamic acid tert-butyl ester 

Downstream Products

• 186547-16-0 7-Methoxynaphthalene-2-sulfonic acid [1-(3-aminomethyl-benzyl)-2-oxo-pyrrolidin-3-(S)-yl]-amide trifluoroacetate 
• 247030-97-3 7-methoxy-naphthalene-2-sulfonic acid [1-(3-cyano-benzyl)-2-oxo-pyrrolidin-3-yl]-(1H-pyrazol-3-ylmethyl)-amide 
• 186551-19-9 3-[<1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl>-7-methoxynaphthalen-2-ylsulfonylamino]-N-propionic acid 
• 186551-20-2 3-[<1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl>-7-methoxynaphthalen-2-ylsulfonylamino]propionamide 
• 186551-49-5 2-[[(S)-1-(3-Cyano-benzyl)-2-oxo-pyrrolidin-3-yl]-(7-methoxy-naphthalene-2-sulfonyl)-amino]-acetamide 
• 186551-29-1 2-[<1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl>-7-methoxynaphthalen-2-ylsulfonylamino]-N-acetic acid 

Relevant academic research and scientific papers

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa

The discovery of a series of non-peptide factor Xa (FXa) inhibitors incorporating 3-(s)-amino-2-pyrrolidinone as a central template is described. After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the amidine group to the S1 pocket of FXa. These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K1 = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases. RPR120844 is an effective anticoagulant in both the rat model of FeCl2-induced carotid artery thrombosis and the rabbit model of jugular vein thrombus formation.

SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.